Search clinical trials for: ORMD-0801 (bid)

Total 4936 results

Oramed, Ltd.
Integrium

Completed

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
The University of Texas Health Science Center at...
Oramed, Ltd.

Completed

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

Type 1 Diabetes

United States
King Hamad University Hospital, Bahrain
Royal College of Surgeons in Ireland - Medical University of Bahrain; Oramed...

Not yet recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Hadassah Medical Organization
Oramed Pharmaceutical Inc.

Completed

Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients

Brittle Type I Diabetes Mellitus

Israel
Oramed, Ltd.
Integrium

Terminated

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Oramed, Ltd.
Integrium

Completed

A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes

Type 1 Diabetes

United States
Oramed, Ltd.
Integrium

Completed

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus Type 2

United States
Oramed, Ltd.
Integrium

Completed

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

T2DM (Type 2 Diabetes Mellitus)

United States
Oblato, Inc.

Recruiting

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma

Astrocytoma | Glioblastoma Multiforme | Oligodendroglioma | High-grade Glioma

United States
Oramed, Ltd.

Completed

A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Oramed, Ltd.

Completed

A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

Belgium
Oramed, Ltd.
Integrium

Terminated

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

T2DM (Type 2 Diabetes Mellitus)

United States
Oramed, Ltd.
Integrium

Completed

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Diabetes Type 2

United States
MediciNova

Completed

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

Interstitial Cystitis

United States
Oramed, Ltd.
Integrium

Completed

A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

Diabetes Mellitus Type 1

United States
Oryn Therapeutics, LLC

Withdrawn

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

COVID-19

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis

Japan
Acer Therapeutics Inc.

Completed

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Post-menopausal Vasomotor Symptoms

United States
Aldeyra Therapeutics, Inc.

Completed

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Dry Eye

United States
Oramed, Ltd.
Integrium

Completed

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Israel
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Balance Therapeutics

Completed

A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001

Healthy | Food Effect

United Kingdom
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Balance Therapeutics

Completed

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Idiopathic Hypersomnia | Narcolepsy Without Cataplexy

United States
Balance Therapeutics

Completed

A Study to Investigate the Mass Balance of BTD-001 (HV103)

Molecular Mechanisms of Pharmacological Action

United Kingdom
Daewon Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects

Healthy Males
University of Copenhagen
Zealand University Hospital

Completed

The Relationship Between Fat Free Mass and Toxicity of Cytostatics in Cancer Patients

Colorectal Cancer | Pancreas Cancer

Denmark
Hamamatsu University

Completed

Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

Gastritis Associated With Helicobacter Pylori

Japan
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF2)

Cystic Fibrosis

United States
Frontera Therapeutics

Recruiting

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Biallelic RPE65 Mutation-associated Retinal Dystrophy

China
Chang Gung Memorial Hospital

Completed

Application of Serial Body Composition Change for Risk Prediction in Treating Patients With Severe Pneumonia

Pneumonia

Taiwan
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of Single Doses of ORM-12741 (Nebula PK 1)

Healthy

Finland
Azura Ophthalmics
Syneos Health; Cliantha Research

Completed

A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Dry Eye | Meibomian Gland Dysfunction

Canada, Australia, New Zealand
Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741

Healthy

France
Oryn Therapeutics, LLC

Completed

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

Rheumatoid Arthritis

United States
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Efficacy and Safety of SJP002 Ophthalmic Solution in Patients With Dry Eye Syndrome.

Dry Eye Syndromes

Korea, Republic of
Orion Corporation, Orion Pharma

Completed

Early Phase I Microdosing Study of ORM-14540 and ORM-12741

Healthy

Finland
SOM Innovation Biotech SA

Completed

Efficacy and Safety of SOM3355 in Huntington's Disease Chorea

Huntington's Chorea

Spain
Haisco Pharmaceutical Group Co., Ltd.

Completed

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia

Postherpetic Neuralgia

China
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH; Nuvisan Pharma Services; EUROCALIN Consortium

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

Healthy

Germany
Santéclair

Completed

The VEPRO Trial: A Cross-Over Randomised Controlled Trial Comparing 2 Corrective Lenses for Patients With Presbyopia (VEPRO)

Presbyopia

France
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)

Healthy

Finland
CorMedix

Completed

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

Contrast-Induced Acute Kidney Injury

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
University of Florida
ADM/Matsutani LLC

Completed

Resistant Maltodextrin Supplementation: Gastrointestinal Health (DEX)

Healthy

United States
Orion Corporation, Orion Pharma

Completed

Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease (ALPO)

Alzheimer's Disease

Finland
Orion Corporation, Orion Pharma

Terminated

Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon (REINO)

Raynaud's Phenomenon

United Kingdom
Zhejiang Haichang Biotech Co., Ltd.

Not yet recruiting

Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)
Cedars-Sinai Medical Center

Completed

The IBD&me Randomized Controlled Trial

Inflammatory Bowel Diseases

United States
Santen Inc.
ActualEyes Inc.

Active, not recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States, France, India

3

Subscribe